Array BioPharma, Inc.’s Oral p38 Inhibitor Demonstrates Significant Analgesic Benefit and Systemic Anti-Inflammatory Activity

BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (Nasdaq: ARRY) today announced positive results from a Phase 2 acute inflammatory dental pain study evaluating the analgesic efficacy of ARRY-797, a small molecule p38 inhibitor, at the 2008 ACR/ARHP Annual Scientific Meeting in San Francisco, Calif. These results confirm a smaller Phase 2 dental pain study reported in May 2008 in which ARRY-797 demonstrated significant analgesic benefit when administered either prior to or following surgery.